Precise HER2 Protein Degradation via Peptide‐Conjugated Photodynamic Therapy for Enhanced Breast Cancer Immunotherapy
Advanced Science · 2025
DOI: 10.1002/advs.202410778 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, 2025. Verfasst von Changyong Guo und 6 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine or Institute of Translational Medicine, Shanghai Engineering Research Center of Organ Repair, Shanghai University, 99 Shangda Road…. Hauptthemen laut MEDLINE: Photochemotherapy, Erb-b2 Receptor Tyrosine Kinases, Breast Neoplasms, Immunotherapy. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Shanghai Rising-Star Program, Science Fund for Distinguished Young Scholars of Fujian Province.
Abstract (Originalsprache)
Breast cancer, the most prevalent malignancy among women, frequently exhibits high HER2 expression, making HER2 a critical therapeutic target. Traditional treatments combining the anti‐HER2 antibody trastuzumab with immunotherapy face limitations due to toxicity and tumor microenvironment immunosuppression. This study introduces an innovative strategy combining HER2‐targeting peptides with the photosensitizer (PSs) pyropheophorbide‐a (Pha) via a gelatinase‐cleavable linker, forming self‐assembling nanoparticles. These nanoparticles actively target breast cancer cells and generate reactive oxygen species (ROS) under near‐infrared light, effectively degrading HER2 proteins. Upon internalization, the linker is cleaved, releasing Pha‐PLG and enhancing intracellular photodynamic therapy (PDT). The Pha‐PLG molecules self‐assemble into nanofibers, prolonging circulation, boosting immune induction, and activating CD8 + T cells, thus promoting a robust anti‐tumor immune response. In vivo, studies confirm superior biosafety, tumor targeting, and HER2 degradation, with increased cytotoxic T cell activity and improved antitumor immunity. This integrated strategy offers a promising new avenue for breast cancer treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Medicine or Institute of Translational Medicine, Shanghai Engineering Research Center of Organ Repair, Shanghai University, 99 Shangda Road, Shanghai, 200444, P. R. China.
- The Center for Basic Research and Innovation of Medicine and Pharmacy (MOE), School of Pharmacy, Second Military Medical University (Naval Medical University), 325 Guohe Road, Shanghai, 200433, P. R. China.
ORCID-Profile: Shipeng He
Förderung
- National Natural Science Foundation of China
- Shanghai Rising-Star Program
- Science Fund for Distinguished Young Scholars of Fujian Province
- Key Technologies Research and Development Program
Zitieren
APA
Guo, C., Gao, F., Wu, G., Li, J., Sheng, C., He, S., & Hu, H. (2025). Precise HER2 Protein Degradation via Peptide‐Conjugated Photodynamic Therapy for Enhanced Breast Cancer Immunotherapy. Advanced Science. https://doi.org/10.1002/advs.202410778
Vancouver
Guo C, Gao F, Wu G, Li J, Sheng C, He S, et al. Precise HER2 Protein Degradation via Peptide‐Conjugated Photodynamic Therapy for Enhanced Breast Cancer Immunotherapy. Advanced Science. 2025. doi:10.1002/advs.202410778
BibTeX
@article{Guo2025,
author = {Guo, Changyong and Gao, Fei and Wu, Guoyuan and Li, Jinqiu and Sheng, Chunquan and He, Shipeng and Hu, Honggang},
title = {Precise HER2 Protein Degradation via Peptide‐Conjugated Photodynamic Therapy for Enhanced Breast Cancer Immunotherapy},
journal = {Advanced Science},
year = {2025},
doi = {10.1002/advs.202410778}
}
EUVIMED